In a report released yesterday, Thomas Smith from SVB Securities maintained a Hold rating on Immunic (IMUX – Research Report), with a price target of $5.00. The company’s shares opened today at $1.67.
Smith covers the Healthcare sector, focusing on stocks such as Immunic, Celldex, and Intercept Pharma. According to TipRanks, Smith has an average return of 38.5% and a 45.14% success rate on recommended stocks.
Currently, the analyst consensus on Immunic is a Moderate Buy with an average price target of $12.67.
See today’s best-performing stocks on TipRanks >>
IMUX market cap is currently $72.38M and has a P/E ratio of -0.43.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
Read More on IMUX:
